ReviewDrugs2023
Pyoderma Gangrenosum: Treatment Options.
Review in Drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 79 citations in OpenAlex.
- Biologic-biologic and biologic-JAK inhibitor combination therapy in refractory systemic autoinflammatory diseases.Seminars in arthritis and rheumatism · 2026Observational
- Selective IL-23 Inhibition in Conventional Treatment-Refractory Pyoderma Gangrenosum: A Multicenter, Retrospective Study.International journal of dermatology · 2026Article
- Guselkumab as a therapeutic option for recalcitrant pyoderma gangrenosum and Crohn disease: a case report and review of the literature.Skin health and disease · 2026Article
- Article
- Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study.Dermatology and therapy · 2026Article
- Pyoderma Gangrenosum Masquerading as Chronic Infective Ulcers: Two Case Reports Across Age Extremes.Clinical case reports · 2026Article
- [Differential diagnoses: skin changes on the leg and their significance].Dermatologie (Heidelberg, Germany) · 2026Article
- Pyoderma gangrenosum: a case report highlighting the importance of early diagnosis and treatment.International journal of surgery case reports · 2026Article
- Remission of recalcitrant pyoderma gangrenosum following chemotherapy for iatrogenic Kaposi sarcoma.JAAD case reports · 2026Article
- Case Report: Successful treatment of pyoderma gangrenosum-like granulomatous liver disease without skin lesions using a TNF-alpha inhibitor.Frontiers in immunology · 2026Article
- Case Report: Localized neutrophilic dermatosis at a split-skin donor site during PD-1 blockade: a unique immune-related adverse event.Frontiers in immunology · 2026Article
- Case Report: A rare co-occurrence of IgA pemphigus and pyoderma gangrenosum associated with IgA-κ type monoclonal gammopathy of undetermined significance: a 19-year diagnostic and therapeutic journey.Frontiers in immunology · 2026Article
- Pyoderma Gangrenosum in Spain: Clinical Features, Therapeutic Management, and Outcomes in a 32-Patient Case Series.Health science reports · 2025Article
- Scalp necrotizing fasciitis after resection of angiolymphoid hyperplasia with eosinophilia misdiagnosed as pyoderma gangrenosum.JAAD case reports · 2025Article
- The diagnostic and therapeutic challenges of pyoderma gangrenosum in a 32-year-old woman with systemic lupus erythematosus: a case report.Annals of medicine and surgery (2012) · 2025Article
- Pyoderma gangrenosum: pathogenetic mechanisms and their implications for treatment.Seminars in immunopathology · 2025Review
- Combination of mechanical debridement and interleukin 12 or interleukin 23 therapy for refractory facial pyoderma gangrenosum with NOD2 mutation.JAAD case reports · 2025Article
- [Pyoderma gangrenosum: pathogenesis, diagnosis, and treatment].Dermatologie (Heidelberg, Germany) · 2025Review
- The Changing Landscape of Clinical Research in Pyoderma Gangrenosum.The Journal of investigative dermatology · 2025Article
- A Curious Case of Cutaneous Pathergy: Pyoderma Gangrenosum in the Setting of Hepatitis C and Cocaine Use.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.